Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.60
Bid: 70.20
Ask: 73.00
Change: 0.00 (0.00%)
Spread: 2.80 (3.989%)
Open: 71.60
High: 0.00
Low: 0.00
Prev. Close: 71.60
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Liquidity Agreement and Total Voting Rights

1 Sep 2021 11:30

RNS Number : 3868K
Novacyt S.A.
01 September 2021
 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Liquidity Agreement Monthly Update and Total Voting Rights

 

Paris, France and Camberley, UK - 1 September 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 August to 31 August 2021, Invest Securities purchased 3,896 ordinary shares at a maximum price of €5.00 and a minimum price of €3.40 and sold 4,646 ordinary shares at a maximum price of €5.03 and a minimum price of €3.49 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 August 2021, is 11,294.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 29 September 2020 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €12.00 for an aggregate maximum purchase price of €200,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRKFLBBFKLEBBX
Date   Source Headline
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Sep 202212:00 pmRNSLiquidity Agreement and Total Voting Rights
4th Aug 20227:00 amRNSLaunch of first fully lyophilised PROmate® assays
1st Aug 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jul 20227:00 amRNSLaunch of research-use-only adenovirus F41 assay
20th Jul 20223:00 pmRNSResults of AGM
15th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSApproval of exsig™ COVID-19 Direct test in the UK
7th Jul 20223:00 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSTrading update and progress against strategy
5th Jul 202211:45 amRNSHoldings in Company
1st Jul 202212:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jun 20227:00 amRNSLaunch of monkeypox assay
21st Jun 20222:00 pmRNSNotice of rescheduled AGM
16th Jun 20227:00 amRNSDHSC dispute update
13th Jun 20227:00 amRNSAGM Voting
1st Jun 20221:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Jun 20227:00 amRNSCTDA approval and CE mark
1st Jun 20227:00 amRNSPublication of Annual Report and AGM voting
13th May 20227:00 amRNSNotice of Annual General Meeting
3rd May 202212:21 pmRNSLiquidity Agreement Update and Total Voting Rights
28th Apr 20227:00 amRNSFull year results and update on growth strategy
26th Apr 20227:00 amRNSDHSC dispute update
20th Apr 20227:00 amRNSNotice of Results and Investor Presentation
12th Apr 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
1st Apr 202211:45 amRNSLiquidity Agreement Update and Total Voting Rights
25th Mar 20225:25 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.